Loading clinical trials...

An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients | Clinical Trials | Clareo Health

COMPLETEDPhase 2NCT01518309

An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients

This is an open-label extension study to assess the long-term safety and tolerability of pimavanserin (ACP-103) in subjects with Parkinson's Disease Psychosis (PDP).

Lead sponsor: ACADIA Pharmaceuticals Inc.•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Related studies

Approved For Marketing

Expanded Access of Pimavanserin for Patients With PD Psychosis

NCT02762591 · Parkinson's Disease Psychosis

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: November 23, 2020Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment39

Start dateNov 2004

Last updatedNov 23, 2020

Condition

Parkinson's Disease Psychosis

Locations shown

Danbury, Connecticut

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 23, 2020Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions